All News
Is There a Standout When Comparing Novel Therapies?
Randomized clinical trials are needed to show efficacy and safety, and are needed to back up the claims and indications for a particular drug. The issue of treatment choice has become challenging, especially when choosing to start or augment therapy.
Read ArticleDRESS Trial Shows TNFi Dose Reduction is Possible - Without Major Flares
Can TNF inhibitor therapy be withdrawn in RA patients who are in remission? The DRESS trial reports the results of randomized trial of 180 RA patients taking either etanercept or adalimumab. Patients were randomly assigned to either usual care (no dose reduction) or a stepwise increase
Read ArticleHLA-DRB1 Alleles Augment RA Severity and TNF Inhibitor Responses
The HLA-DRB1 haplotype is a known risk factor for RA.
Read ArticlePoisoning deaths involving opioid analgesics - NY State
Between 1999 and 2013 opiate-related deaths nearly quadrupled, with the death rate rising from 1.4 to 5.1 deaths per 100,000. These alarming statistics have lead to greater regulation and oversight to opiate use.
Read Article